(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 February 2009 (05.02.2009)

PCT

(10) International Publication Number
WO 2009/016460 A8

(51) International Patent Classification:
C07D 401/14 (2006.01) *A61K 31/4439* (2006.01)
C07D 403/14 (2006.01) *A61K 31/506* (2006.01)
C07D 471/04 (2006.01) *A61P 35/00* (2006.01)
C07D 487/04 (2006.01)

(21) International Application Number:
PCT/IB2008/001952

(22) International Filing Date:
21 July 2008 (21.07.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/953,235 1 August 2007 (01.08.2007) US
61/080,054 11 July 2008 (11.07.2008) US

(71) Applicant *(for all designated States except US)*: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventors; and


(75) Inventors/Applicants *(for US only)*: **CUI, Jingrong Jean** [US/US]; Agouron Pharmaceuticals Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, California 92121 (US). **DEAL, Judith Gail** [US/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **GU, Danlin** [CN/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **GUO, Chuangxing** [US/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **JOHNSON, Mary Catherine** [US/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **KANIA, Robert Steven** [US/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **KEPHART, Susan Elizabeth** [US/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **LINTON, Maria Angelica** [US/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **MCALPINE, Indrawan James** [US/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **PAIRISH, Mason Alan** [CN/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **PALMER, Cynthia Louise** [US/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US).

(74) Agents: **FULLER, Grover, F.** et al.; Pfizer Inc., 150 East 42nd Street, New York, NY 10017 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,

[Continued on next page]

(54) Title: PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS



(I)

(57) Abstract: The present invention is directed to compounds of Formula (I) and to pharmaceutically acceptable salts thereof, their synthesis, and their use as Raf inhibitors.

WO 2009/016460 A8

MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(88) Date of publication of the international search report:
26 March 2009

(48) Date of publication of this corrected version:
15 October 2009

(15) Information about Correction:
see Notice of 15 October 2009